Autologous hematopoietic stem cell transplantation improves survival outcomes in peripheral T-cell lymphomas: a multicenter retrospective real-world study.

"Declarations Ethics approvalAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the institutional review board of the lead institution of Peking University Cancer Hospital & Institute and all other participating institutions, and the necessity for patient informed consent was waived (No. 2018KT84). Consent to participateThe informed consent was waived based on the use of a deidentified data set. Consent for publicationNot applicable. Competing interestsThe authors declare no competing interests. Competing interests The authors declare no competing interests."

"Funding The study was funded by the Capital’s Funds for Health Improvement and Research (Nos. 2022–4-2156, 2020-2Z-2157, and 2022–1-2152), the National Natural Science Foundation of China (Nos. 82070205, 81870154, 81972807, 81670187, 81970179, and 81700197), the Beijing Natural Science Foundation (Nos. 7202025 and 7202026), the Beijing Municipal Science & Technology Commission (Z181100001918019), the Cultivation Plan in Haidian District (HP2022-19–503004), and the Beijing Hospital Authority Cultivation Plan (PX2022046)."